Midodrine plus albumin for ascites control
Not Applicable
- Conditions
- Health Condition 1: K746- Other and unspecified cirrhosis ofliver
- Registration Number
- CTRI/2023/05/052752
- Lead Sponsor
- Mylan Pharmaceuticals Pvt Ltd
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
All cirrhotic (sinusoidal portal hypertension) patients, age above 18 years, either gender, irrespective of aetiology, with refractoryascites, without acute kidney injury at the time of enrolment.
Exclusion Criteria
Patients with
(i) cardiac conditions such as ischemic heart disease, congestive cardiac failure,
(ii) hepatic encephalopathy
(iii) active sepsis such as spontaneous bacterial peritonitis or blood culture positivity,
(iv) tuberculous ascites
(v) chronic kidney disease,
(vi) active malignancy
(vii) any contraindications to oral midodrine administration as listed above
(viii) any contraindications to intravenous albumin administration as listed above
(ix) not willing to participate in the study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method